Apimeds faces hostile takeover attempt by Inscobee; company says consent void, files emergency action

Apimeds Pharmaceuticals US, Inc.

On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.
Company states the consent violates the irrevocable proxy granted under the Support Agreement from Dec 1, 2025.
Inscobee used 6,416,365 shares subject to proxy; without those, consent lacks majority under Delaware law.
Company will file emergency action in Delaware Court of Chancery under 8 Del. C. § 225 to void consent.
Purported new board approved business expansions without authorization; company disputes them.

item 5.02item 5.03item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.